{"DataElement":{"publicId":"2936117","version":"1","preferredName":"AIDS Malignancy Consortium Patient Exclusion Clinical Trial Eligibility Criteria 061 Type","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by the NCI.","longName":"AMC_PT_E_CTEC_061_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518234","version":"1","preferredName":"AIDS Malignancy Consortium Patient Exclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by the NCI.","longName":"AMC_PT_EXCLU_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518232","version":"1","preferredName":"Exclusion Clinical Trial Eligibility Criteria","preferredDefinition":"Exclusion; the act of restricting entrance or barring from participation.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25370:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exclusion Criteria","conceptCode":"C25370","definition":"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC88111-1844-69E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC88111-1855-69E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2936099","version":"1","preferredName":"061 Exclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility exclusion criteria for an AIDS Malignancy Consortium 061 protocol.","longName":"061_EXCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Does the participant have clinically significant cardiovascular disease, including uncontrolled hypertension (diastolic blood pressure >=100 mmHg despite optimal medical therapy) or unstable angina","valueDescription":"Does the participant have clinically significant cardiovascular disease, including uncontrolled hypertension (diastolic blood pressure >=100 mmHg despite optimal medical therapy) or unstable angina","ValueMeaning":{"publicId":"2961459","version":"1","preferredName":"Does the participant have clinically significant cardiovascular disease, including uncontrolled hypertension (diastolic blood pressure >=100 mmHg despite optimal medical therapy) or unstable angina","longName":"2961459","preferredDefinition":"Does the participant have clinically significant cardiovascular disease, including uncontrolled hypertension (diastolic blood pressure >=100 mmHg despite optimal medical therapy) or unstable angina","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B566-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"78AB07DC-B57F-F05E-E040-BB89AD43180B","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"ONEDATA","dateModified":"2009-11-18","deletedIndicator":"No"},{"value":"Does the participant have ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade >= 2","valueDescription":"Does the participant have ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade >= 2","ValueMeaning":{"publicId":"2961458","version":"1","preferredName":"Does the participant have ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade >= 2","longName":"2961458","preferredDefinition":"Does the participant have ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade >= 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B543-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"78AB07DC-B55C-F05E-E040-BB89AD43180B","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"ONEDATA","dateModified":"2009-11-18","deletedIndicator":"No"},{"value":"Does the participant have an abnormal Left Ventricular Ejection Fraction per institutional standards","valueDescription":"Does the participant have an abnormal Left Ventricular Ejection Fraction per institutional standards","ValueMeaning":{"publicId":"2982795","version":"1","preferredName":"Does the participant have an abnormal Left Ventricular Ejection Fraction per institutional standards","longName":"2982795","preferredDefinition":"Does the participant have an abnormal Left Ventricular Ejection Fraction per institutional standards","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C963920-4B16-D54C-E040-BB89AD43067B","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C963920-4B2F-D54C-E040-BB89AD43067B","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Does the participant have another severe and/or life-threatening medical disease","valueDescription":"Does the participant have another severe and/or life-threatening medical disease","ValueMeaning":{"publicId":"2649485","version":"1","preferredName":"Does the participant have another severe and/or life-threatening medical disease","longName":"2649485","preferredDefinition":"Does the participant have another severe and/or life-threatening medical disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32652E60-3777-3C62-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AAF3-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"If the participant is female, is she pregnant or breast-feeding","valueDescription":"If the participant is female, is she pregnant or breast-feeding","ValueMeaning":{"publicId":"2649481","version":"1","preferredName":"If the participant is female, is she pregnant or breast-feeding","longName":"2649481","preferredDefinition":"If the participant is female, is she pregnant or breast-feeding","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32655A77-934F-3C34-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AAFD-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have a pre-existing thyroid abnormality that cannot be maintained with medication to keep measures of thyroid stimulating hormone within the normal range","valueDescription":"Does the participant have a pre-existing thyroid abnormality that cannot be maintained with medication to keep measures of thyroid stimulating hormone within the normal range","ValueMeaning":{"publicId":"2936100","version":"1","preferredName":"Does the participant have a pre-existing thyroid abnormality that cannot be maintained with medication to keep measures of thyroid stimulating hormone within the normal range","longName":"2936100","preferredDefinition":"Does the participant have a pre-existing thyroid abnormality that cannot be maintained with medication to keep measures of thyroid stimulating hormone within the normal range","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AB07-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AB20-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have a psychiatric illness that would limit compliance with study requirements","valueDescription":"Does the participant have a psychiatric illness that would limit compliance with study requirements","ValueMeaning":{"publicId":"2936101","version":"1","preferredName":"Does the participant have a psychiatric illness that would limit compliance with study requirements","longName":"2936101","preferredDefinition":"Does the participant have a psychiatric illness that would limit compliance with study requirements","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AB2A-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AB43-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have a QTc interval > 500 msec","valueDescription":"Does the participant have a QTc interval > 500 msec","ValueMeaning":{"publicId":"2936102","version":"1","preferredName":"Does the participant have a QTc interval > 500 msec","longName":"2936102","preferredDefinition":"Does the participant have a QTc interval > 500 msec","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AB4D-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AB66-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have serious cardiac arrhythmia requiring medication","valueDescription":"Does the participant have serious cardiac arrhythmia requiring medication","ValueMeaning":{"publicId":"2936103","version":"1","preferredName":"Does the participant have serious cardiac arrhythmia requiring medication","longName":"2936103","preferredDefinition":"Does the participant have serious cardiac arrhythmia requiring medication","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AB70-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AB89-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have a history of serious ventricular arrhythmia (ventricular tachycardia (VT) or ventricular fibrillation (VF) >= 3 beats in a row)","valueDescription":"Does the participant have a history of serious ventricular arrhythmia (ventricular tachycardia (VT) or ventricular fibrillation (VF) >= 3 beats in a row)","ValueMeaning":{"publicId":"2936104","version":"1","preferredName":"Does the participant have a history of serious ventricular arrhythmia (ventricular tachycardia (VT) or ventricular fibrillation (VF) >= 3 beats in a row)","longName":"2936104","preferredDefinition":"Does the participant have a history of serious ventricular arrhythmia (ventricular tachycardia (VT) or ventricular fibrillation (VF) >= 3 beats in a row)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AB93-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-ABAC-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Has the participant had a myocardial infarction, severe/unstable angina, coronary artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of study entry","valueDescription":"Has the participant had a myocardial infarction, severe/unstable angina, coronary artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of study entry","ValueMeaning":{"publicId":"2936107","version":"1","preferredName":"Has the participant had a myocardial infarction, severe/unstable angina, coronary artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of study entry","longName":"2936107","preferredDefinition":"Has the participant had a myocardial infarction, severe/unstable angina, coronary artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of study entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-ABFC-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AC15-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease","valueDescription":"Does the participant have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease","ValueMeaning":{"publicId":"2936109","version":"1","preferredName":"Does the participant have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease","longName":"2936109","preferredDefinition":"Does the participant have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AC42-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AC5B-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Will the participant undergo concurrent treatment with medications, other than antiretroviral drugs used to treat HIV infection, that are known to inhibit or induce CYP3A4","valueDescription":"Will the participant undergo concurrent treatment with medications, other than antiretroviral drugs used to treat HIV infection, that are known to inhibit or induce CYP3A4","ValueMeaning":{"publicId":"2936110","version":"1","preferredName":"Will the participant undergo concurrent treatment with medications, other than antiretroviral drugs used to treat HIV infection, that are known to inhibit or induce CYP3A4","longName":"2936110","preferredDefinition":"Will the participant undergo concurrent treatment with medications, other than antiretroviral drugs used to treat HIV infection, that are known to inhibit or induce CYP3A4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AC65-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AC7E-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Has the participant had major surgery or radiation within 3 weeks prior to study entry","valueDescription":"Has the participant had major surgery or radiation within 3 weeks prior to study entry","ValueMeaning":{"publicId":"2936111","version":"1","preferredName":"Has the participant had major surgery or radiation within 3 weeks prior to study entry","longName":"2936111","preferredDefinition":"Has the participant had major surgery or radiation within 3 weeks prior to study entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AC88-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-ACA1-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Has the participant received antineoplastic therapy, including investigational drug or standard treatment, within 2 weeks of study entry? (Must be able to demonstrate adequate recovery from prior therapy-related toxicities.)","valueDescription":"Has the participant received antineoplastic therapy, including investigational drug or standard treatment, within 2 weeks of study entry? (Must be able to demonstrate adequate recovery from prior therapy-related toxicities.)","ValueMeaning":{"publicId":"2936112","version":"1","preferredName":"Has the participant received antineoplastic therapy, including investigational drug or standard treatment, within 2 weeks of study entry? (Must be able to demonstrate adequate recovery from prior therapy-related toxicities.)","longName":"2936112","preferredDefinition":"Has the participant received antineoplastic therapy, including investigational drug or standard treatment, within 2 weeks of study entry? (Must be able to demonstrate adequate recovery from prior therapy-related toxicities.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-ACAB-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-ACC4-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Has the participant had acute treatment for an infection or other serious medical illness within 14 days prior to study entry","valueDescription":"Has the participant had acute treatment for an infection or other serious medical illness within 14 days prior to study entry","ValueMeaning":{"publicId":"2936113","version":"1","preferredName":"Has the participant had acute treatment for an infection or other serious medical illness within 14 days prior to study entry","longName":"2936113","preferredDefinition":"Has the participant had acute treatment for an infection or other serious medical illness within 14 days prior to study entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-ACCE-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-ACE7-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have a concurrent active opportunistic infection","valueDescription":"Does the participant have a concurrent active opportunistic infection","ValueMeaning":{"publicId":"2936114","version":"1","preferredName":"Does the participant have a concurrent active opportunistic infection","longName":"2936114","preferredDefinition":"Does the participant have a concurrent active opportunistic infection","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-ACF1-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E60D2-AD0A-68B2-E040-BB89AD434AF2","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AADF-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Exclusion Criteria","type":"Preferred Question Text","description":"Exclusion Criteria","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E60D2-AD37-68B2-E040-BB89AD434AF2","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}